Literature DB >> 27106232

Potential Role of TRAIL in Metastasis of Mutant KRAS Expressing Lung Adenocarcinoma.

Shyama Pal1, Prayag J Amin1, K B Sainis1, Bhavani S Shankar2.   

Abstract

Apo2L/tumor necrosis factor (TNF)-α-related apoptosis-inducing ligand (TRAIL, TNFSF10) is an important cytokine in the tumor microenvironment and plays a major role in the balance of cell survival/death pathways. Bioinformatic analyses of 839 adenocarcinoma (AC) and 356 squamous cell lung carcinoma patient data (SCC) by cBioPortal (genomic analyses) shows that TRAIL expression leads to differential outcomes of disease free survival in AC and SCC. Oncomine datamining (transcript analyses) reveal that TRAIL is upregulated in 167 SCC as compared to 350 AC patients from six data sets. Genomic analyses using cBioPortal revealed high rates of KRAS mutation in AC accompanied by higher incidence of metastasis and increased amplifications of TRAIL gene in SCC. Bioinformatic analyses of an additional lung cancer patient database also showed that risk of disease progression was significantly increased with high TRAIL expression in AC (461 samples). In vitro studies demonstrated that TRAIL increased phosphorylation of ERK only in adenocarcinoma cell lines with mutant KRAS. This was associated with increased migration that was abrogated by MEK inhibitor PD98059. Effects of increased migration induced by TRAIL persisted even after exposure to ionizing radiation with suppression of DNA damage response. These results help understand the role of TRAIL signaling in metastasis which is essential to develop strategies to revert these signals into pro-apoptotic pathways.

Entities:  

Keywords:  Adenocarcinoma; ERK signaling; Mutant KRAS; Oncomine; Squamous cell carcinoma; TRAIL; cBioPortal

Year:  2016        PMID: 27106232      PMCID: PMC5264657          DOI: 10.1007/s12307-016-0184-3

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  26 in total

1.  ONCOMINE: a cancer microarray database and integrated data-mining platform.

Authors:  Daniel R Rhodes; Jianjun Yu; K Shanker; Nandan Deshpande; Radhika Varambally; Debashis Ghosh; Terrence Barrette; Akhilesh Pandey; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2004 Jan-Feb       Impact factor: 5.715

2.  TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma.

Authors:  A Trauzold; D Siegmund; B Schniewind; B Sipos; J Egberts; D Zorenkov; D Emme; C Röder; H Kalthoff; H Wajant
Journal:  Oncogene       Date:  2006-06-05       Impact factor: 9.867

3.  TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.

Authors:  A Munshi; G Pappas; T Honda; T J McDonnell; A Younes; Y Li; R E Meyn
Journal:  Oncogene       Date:  2001-06-28       Impact factor: 9.867

4.  IFN-gamma inhibition of TRAIL-induced IAP-2 upregulation, a possible mechanism of IFN-gamma-enhanced TRAIL-induced apoptosis.

Authors:  Sang-Youel Park; Timothy R Billiar; Dai-Wu Seol
Journal:  Biochem Biophys Res Commun       Date:  2002-02-22       Impact factor: 3.575

5.  Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

Authors:  Heidi LeBlanc; David Lawrence; Eugene Varfolomeev; Klara Totpal; John Morlan; Peter Schow; Sharon Fong; Ralph Schwall; Dominick Sinicropi; Avi Ashkenazi
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

6.  Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells.

Authors:  Zi Li; Xiuling Xu; Lang Bai; Wenshu Chen; Yong Lin
Journal:  J Biol Chem       Date:  2011-04-27       Impact factor: 5.157

Review 7.  Emerging roles of proteases in tumour suppression.

Authors:  Carlos López-Otín; Lynn M Matrisian
Journal:  Nat Rev Cancer       Date:  2007-10       Impact factor: 60.716

Review 8.  Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family.

Authors:  K Azijli; B Weyhenmeyer; G J Peters; S de Jong; F A E Kruyt
Journal:  Cell Death Differ       Date:  2013-04-12       Impact factor: 15.828

Review 9.  Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Authors:  F Wei; J Yan; D Tang
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

10.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes.

Authors:  Anne E Carpenter; Thouis R Jones; Michael R Lamprecht; Colin Clarke; In Han Kang; Ola Friman; David A Guertin; Joo Han Chang; Robert A Lindquist; Jason Moffat; Polina Golland; David M Sabatini
Journal:  Genome Biol       Date:  2006-10-31       Impact factor: 13.583

View more
  11 in total

1.  Regulation of death receptor signaling by the autophagy protein TP53INP2.

Authors:  Saška Ivanova; Mira Polajnar; Alvaro Jesus Narbona-Perez; Maria Isabel Hernandez-Alvarez; Petra Frager; Konstantin Slobodnyuk; Natalia Plana; Angel R Nebreda; Manuel Palacin; Roger R Gomis; Christian Behrends; Antonio Zorzano
Journal:  EMBO J       Date:  2019-04-12       Impact factor: 11.598

Review 2.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy.

Authors:  Silvia von Karstedt; Antonella Montinaro; Henning Walczak
Journal:  Nat Rev Cancer       Date:  2017-05-24       Impact factor: 60.716

3.  RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer.

Authors:  Bo Ram Kim; Seong Hye Park; Yoon A Jeong; Yoo Jin Na; Jung Lim Kim; Min Jee Jo; Soyeon Jeong; Hye Kyeong Yun; Sang Cheul Oh; Dae-Hee Lee
Journal:  Oncogene       Date:  2019-01-28       Impact factor: 9.867

4.  BRD7 Acts as a Tumor Suppressor Gene in Lung Adenocarcinoma.

Authors:  Yushun Gao; Bing Wang; Shugeng Gao
Journal:  PLoS One       Date:  2016-08-31       Impact factor: 3.240

5.  Peritoneum as the sole distant metastatic site of lung adenosquamous cell carcinoma: a case report.

Authors:  Pan Yang; Wei-Liang Li; Jeff-X Zhou; Yu-Bo Yang; Xia-Xiang Jin
Journal:  J Med Case Rep       Date:  2017-09-27

Review 6.  The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials.

Authors:  Martin Snajdauf; Klara Havlova; Jiri Vachtenheim; Andrej Ozaniak; Robert Lischke; Jirina Bartunkova; Daniel Smrz; Zuzana Strizova
Journal:  Front Mol Biosci       Date:  2021-03-10

Review 7.  Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling.

Authors:  You-Take Oh; Shi-Yong Sun
Journal:  Biomolecules       Date:  2021-03-26

8.  Pathway-focused PCR array profiling of CAL-27 cell with over-expressed ZNF750.

Authors:  Li Pan; Hongli Yang; Wenqiang Tang; Cong Xu; Shuangfeng Chen; Zhen Meng; Keyi Li; Haiying Chen
Journal:  Oncotarget       Date:  2017-12-09

9.  Recombinant Newcastle disease virus expressing human IFN-λ1 (rL-hIFN-λ1)-induced apoptosis of A549 cells is connected to endoplasmic reticulum stress pathways.

Authors:  Yulan Yan; Sha Liu; Mi Li; Yinghai Zhao; Xiaomei Shao; Min Hang; Xuefeng Bu
Journal:  Thorac Cancer       Date:  2018-09-23       Impact factor: 3.500

10.  TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas.

Authors:  Huanyu Zhang; Guohui Qin; Chaoqi Zhang; Huiyun Yang; Jinyan Liu; Hongwei Hu; Peng Wu; Shasha Liu; Li Yang; Xinfeng Chen; Xueke Zhao; Lidong Wang; Yi Zhang
Journal:  J Exp Clin Cancer Res       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.